New Phase 3 trial: A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 Years — EMS
Why now
Thesis: Phase 3 registration for EMS allergic rhinitis drug
Catalyst to watch: Trial enrollment or efficacy results
Main risk: Sponsor not in allowed ticker set
Why it matters
Phase 3 registration for an EMS allergic rhinitis drug; sponsor not in allowed ticker set.
Details
Sponsor: EMS; Status: Not Yet Recruiting; Conditions: Persistent Allergic Rhinitis; Interventions: DEP114, Desloratadine; Enrollment: 316 (estimated); First posted: 2026-09-22; NCT: NCT07835074
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC